This Article Full Text Full Text (PDF) All Versions of this Article: 36/2/332    most recent 01.STR.0000152273.24063.f7v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kilic, E. Articles by Hermann, D. M. Search for Related Content PubMed PubMed Citation Articles by Kilic, E. Articles by Hermann, D. M. Related Collections Cerebrovascular disease/stroke Neuroprotectors Thrombolysis

(Stroke. 2005;36:332.)
© 2005 American Heart Association, Inc.

Original Contributions

Aggravation of Focal Cerebral Ischemia by Tissue Plasminogen Activator Is Reversed by 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor but Does Not Depend on Endothelial NO Synthase

Ertugrul Kilic, PhD; Ülkan Kilic, MD; Christian M. Matter, MD; Thomas F. Lüscher, MD; Claudio L. Bassetti, MD Dirk M. Hermann, MD

From the Department of Neurology (E.K, U.K., C.L.B., D.M.H.), University Hospital Zurich; and Cardiovascular Research (C.M.M., T.F.L.), Physiological Institute, University of Zurich, Switzerland.

Correspondence to Dr Ertugrul Kilic, Department of Neurology, University Hospital, Frauenklinikstr. 26, CH-8091 Zürich, Switzerland. E-mail ertugrul.kilic{at}usz.ch

Background and Purpose— It has repeatedly been reported that the thrombolytic tissue plasminogen activator (tPA) may aggravate ischemic injury after stroke. The underlying mechanisms, however, remain unknown. We hypothesized that tPA induces an inhibition of endothelial NO synthase (eNOS) after focal ischemia that is responsible for ischemic damage and may be restored by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.

Methods— We examined the effects of tPA, administered either alone or in combination with rosuvastatin, on ischemic injury, on eNOS expression, and cell signaling after 90 minutes of intraluminal middle cerebral artery occlusion.

Results— In wild-type mice, tPA delivered immediately after ischemia significantly increased infarct volume 24 hours after reperfusion. Coadministration of rosuvastatin completely reversed the tPA-induced brain damage. Western blots of ischemic brain lysates showed that tPA markedly diminished eNOS levels, increased extracellular regulated kinase (ERK)-2, and decreased MAP kinase/p38 activity. Cotreatment with rosuvastatin prevented the decrease in eNOS, reduced ERK-1/-2 and normalized p38 levels. To elucidate the role of eNOS in tPA-induced ischemic injury, we also evaluated tPA effects in eNOS knockout mice. In eNOS knockout animals, tPA again significantly increased infarct size after transient focal ischemia.

Conclusions— In a mouse model of focal cerebral ischemia, tPA induces eNOS inhibition, ERK-2 activation, and p38 inhibition, possibly as part of a more complex signaling response exacerbating brain injury. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition reverses the effects of tPA by a mechanism independent of eNOS.

Key Words: hydroxymethylglutaryl-CoA reductase inhibitors • ischemia • stroke, acute • thrombolysis

This article has been cited by other articles:

				M. S. Kostapanos, H. J. Milionis, and M. S. Elisaf An Overview of the Extra-Lipid Effects of Rosuvastatin Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2008; 13(3): 157 - 174. [Abstract] [PDF]

				V. Prinz, U. Laufs, K. Gertz, G. Kronenberg, M. Balkaya, C. Leithner, U. Lindauer, and M. Endres Intravenous Rosuvastatin for Acute Stroke Treatment: An Animal Study Stroke, February 1, 2008; 39(2): 433 - 438. [Abstract] [Full Text] [PDF]

				L. Zhang, Z. G. Zhang, X. S. Liu, A. Hozeska-Solgot, and M. Chopp The PI3K/Akt Pathway Mediates the Neuroprotective Effect of Atorvastatin in Extending Thrombolytic Therapy After Embolic Stroke in the Rat Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2470 - 2475. [Abstract] [Full Text] [PDF]

				C. Orset, R. Macrez, A. R. Young, D. Panthou, E. Angles-Cano, E. Maubert, V. Agin, and D. Vivien Mouse Model of In Situ Thromboembolic Stroke and Reperfusion Stroke, October 1, 2007; 38(10): 2771 - 2778. [Abstract] [Full Text] [PDF]

				D. M. Hermann and C. M. Matter Tissue Plasminogen Activator Induced Reperfusion Injury After Stroke Revisited Circulation, July 24, 2007; 116(4): 363 - 365. [Full Text] [PDF]

				S. Wang, S.-R. Lee, S.-Z. Guo, W. J. Kim, J. Montaner, X. Wang, and E. H. Lo Reduction of Tissue Plasminogen Activator-Induced Matrix Metalloproteinase-9 by Simvastatin in Astrocytes Stroke, July 1, 2006; 37(7): 1910 - 1912. [Abstract] [Full Text] [PDF]

				L. Zhang, Z. G. Zhang, G. L. Ding, Q. Jiang, X. Liu, H. Meng, A. Hozeska, C. Zhang, L. Li, D. Morris, et al. Multitargeted Effects of Statin-Enhanced Thrombolytic Therapy for Stroke With Recombinant Human Tissue-Type Plasminogen Activator in the Rat Circulation, November 29, 2005; 112(22): 3486 - 3494. [Abstract] [Full Text] [PDF]